Anna Berkenblit Sells 5,851 Shares of ImmunoGen, Inc. (IMGN) Stock

Share on StockTwits

ImmunoGen, Inc. (NASDAQ:IMGN) VP Anna Berkenblit sold 5,851 shares of the company’s stock in a transaction that occurred on Monday, September 10th. The stock was sold at an average price of $9.46, for a total value of $55,350.46. Following the sale, the vice president now directly owns 138,620 shares of the company’s stock, valued at approximately $1,311,345.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

IMGN opened at $9.26 on Friday. ImmunoGen, Inc. has a 1-year low of $4.80 and a 1-year high of $13.41. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.76 and a quick ratio of 5.73. The company has a market capitalization of $1.39 billion, a PE ratio of -12.35 and a beta of 1.95.

ImmunoGen (NASDAQ:IMGN) last posted its quarterly earnings data on Friday, July 27th. The biotechnology company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.02). The firm had revenue of $9.29 million during the quarter, compared to the consensus estimate of $14.12 million. The company’s revenue for the quarter was down 76.2% compared to the same quarter last year. During the same period last year, the company earned ($0.10) earnings per share. sell-side analysts predict that ImmunoGen, Inc. will post -1.19 EPS for the current year.

IMGN has been the subject of several research reports. ValuEngine cut ImmunoGen from a “strong-buy” rating to a “buy” rating in a research report on Thursday, June 28th. BidaskClub raised ImmunoGen from a “hold” rating to a “buy” rating in a research report on Thursday, June 21st. HC Wainwright set a $18.00 price objective on ImmunoGen and gave the company a “buy” rating in a research report on Wednesday, June 13th. Finally, Cowen reissued a “hold” rating on shares of ImmunoGen in a research report on Thursday, May 17th. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $12.42.

Hedge funds and other institutional investors have recently modified their holdings of the stock. SG Americas Securities LLC acquired a new position in shares of ImmunoGen in the second quarter valued at $115,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of ImmunoGen by 198.5% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,144 shares of the biotechnology company’s stock valued at $117,000 after purchasing an additional 7,411 shares in the last quarter. Quantitative Systematic Strategies LLC acquired a new position in shares of ImmunoGen in the first quarter valued at $126,000. Private Advisor Group LLC acquired a new position in shares of ImmunoGen in the second quarter valued at $131,000. Finally, Great West Life Assurance Co. Can raised its stake in shares of ImmunoGen by 75.1% in the second quarter. Great West Life Assurance Co. Can now owns 15,767 shares of the biotechnology company’s stock valued at $153,000 after purchasing an additional 6,763 shares in the last quarter. Institutional investors and hedge funds own 83.77% of the company’s stock.

About ImmunoGen

ImmunoGen, Inc, a clinical-stage biotechnology company, focuses on developing antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm, as well as coltuximab ravtansine, a CD19-targeting ADC, which is in Phase II trial for DLBCL.

Featured Article: What is a Leveraged Buyout (LBO)?

Insider Buying and Selling by Quarter for ImmunoGen (NASDAQ:IMGN)

Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Clorox  Stock Rating Upgraded by Argus
Clorox Stock Rating Upgraded by Argus
Advanced Micro Devices  Receives New Coverage from Analysts at KeyCorp
Advanced Micro Devices Receives New Coverage from Analysts at KeyCorp
Achillion Pharmaceuticals  Raised to Sell at BidaskClub
Achillion Pharmaceuticals Raised to Sell at BidaskClub
Holly Energy Partners  Downgraded to Underweight at Barclays
Holly Energy Partners Downgraded to Underweight at Barclays
Sierra Oncology  Stock Rating Upgraded by Zacks Investment Research
Sierra Oncology Stock Rating Upgraded by Zacks Investment Research
Traders Buy Shares of VanEck Vectors J.P. Morgan EM Local Currency Bond ETF  on Weakness
Traders Buy Shares of VanEck Vectors J.P. Morgan EM Local Currency Bond ETF on Weakness


Leave a Reply

 
© 2006-2018 Zolmax.